|
|
name  click to compare prices |
| Afrin | | Bain de Soleil | | Canji, Chlor-Trimeton, Clarinex, Claritin, Clarityne, Coppertone, Correctol | | Drixoral | | Intron A | | Lotrimil | | Nasonex, NeoGenesis Pharmaceuticals | | Organon Biosciences | | Proventil | | Ralgro, Remicade | Schering-Plough  , Scholl (licence in the United States), Solarcaine | | Tinactin | | Vancenase, Vanceril |
» Shop local, ethical and at the best price on Ethishop  |
|
| |
|
| shareholder | country | % | source |
|
year | business source |
| 2006 | Schering Plough is the world's sixteenth-largest pharmaceutical group. | Les Echos |
|
| country | address & contact : production type incentive source |
 Bermuda | Garden Insurance Co., Ltd : |
| Bermuda | Schering-Plough China, Ltd : |
 Hong-Kong | Schering-Plough Animal Health Ltd : |
 Ireland | Loftus Bryan Chemicals Ltd : |
| Ireland | Mallinckrodt Veterinary Ltd : |
| Ireland | Schering-Plough Pensions Ireland Ltd : |
| Ireland | Avondale Chemical Co., Ltd : |
| Ireland | Chemibiotic (Ireland) Ltd : |
 Mexico | DISTRITO FEDERAL XOCHIMILCO 16 DE SEPTIEMBRE 301 XALTOCAN & 015 7284444 : Sistema de Informacion de la Industria Maquiladora |
 Panama | Colombia Veterinary Holdings, Inc : |
 Philippines | Plough Consumer Products (Philippines) Inc : |
 Singapore | 2 usines : Zetia, Peg-Intron, Remicade  Les Echos |
| Singapore | Schering-Plough Animal-Health Pte. Ltd : |
|
| year name | photo position; compensation source |
| 2002Connors, Joseph |  Président du Conseil; salary: 1,58 million US$; stock-options: 0,95 million US$;
|
|
| year | employees <> | social impact : country source |
| 2008 | -330 | Merger/Acquisition: Schering Plow reorganized its sales force after the acquisition of the laboratory Organon.: France | Les Echos |
| 2008 | -1000 | Internal restructuring: Schering Plough launches a restructuring plan to save 1,5 billion dollars because of the fall of the sales of its anticholesterol Vytorin and Zetia. It cuts sales jobs.: United States of America | Les Echos |
| 2006 | -1100 | Internal restructuring: Schering-Plough will streamline or phase out operations at its manufacturing facilities in Puerto Rico and New Jersey. The plan will cost $250 million and save the company $100 million a year.: United States of America | Reuters |
| 2003 | -900 | Internal restructuring: | AP |
| 1989 | -105 | | Canadian Labour Congress |
|
| year | employees <> | social impact : country source |
|
| year | country : consequences source |
|
| year | country : consequences source |
|
| year | financial misdemeanor | sales | income | | | source |
| 2008 |
| 18,5 | 1,79 | | | billion US$ | |
| 2007 |
| 10,59 | -1,59 | | | billion US$ | |
| 2006 |
| 10,6 | 1,06 | | | billion Eu€ | Les Echos |
| 2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. Shering-Plough settles the case for 435 million dollars. |
| | | | | | Bloomberg |
| 2004 |
| | -0,9 | | | billion US$ | Les Echos |
| 2003 |
| 8,33 | -0,09 | | | billion US$ | |
| 2002 |
| 10,18 | 1,97 | | | billion US$ | |
| 2002 |
Allegedly sold misbranded medicines, submitted false pricing data or offered free samples to lure customers |
| | | | | | Bloomberg |
| 2000 |
| 9,82 | 2,42 | | | billion US$ | |
| 1999 |
| 9,18 | 2,11 | | | billion US$ | |
| 1998 |
| 8,08 | 1,76 | | | billion US$ | |
|
| year | financial misdemeanor | sales | income | assets | buyback | source |
|
| year | purpose : intermediary/lobby : institution source |
| 2001 | Access to foreign market (through MAI, WTO, GATS), prevent binding environmental regulations : USCIB (US Council For International Business) : : US Government  translate | USCIB |
| 2000 | Lobbying of US authorities to extend the patent protection of its antiallergic Clarityne (sales of 2 billion US$ per year) by 3 years. : amount: 4300 thousand US$ translate | Le Monde Diplomatique |
| 2000 | Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translate | Washington Post |
| 2000 | Lift the ban on bovine growth hormons, the moratorium on GMOs : EFPIA (European Federation of Pharmaceutical Industry Associations) : : European Commission translate | EFPIA |
| 2000 | lift the ban on bovine growth hormon : FEDESA : : European Commission translate | Fedesa |
| 1998 | Regulation favorable to company's interests : Contribution to Candidate's Political Action Committee : amount: 170 thousand US$ : US President, Congress, Senate translate | Center for Responsive Politics |
| 1997 | Legislation favorable to company's interests : Direct donation : amount: 265 thousand US$ : US President, Congress, Senate translate | Center for Responsive Politics |
| 1997 | Legislation favorable to company's interests : Direct donation : amount: 2683 thousand US$ : US President, Congress, Senate translate | Center for Responsive Politics |
|
| year | purpose : intermediary/lobby : institution source |
|
| year | dubious practice : image source |
| 2006 | Deceptive advertising: Plainte collective pour publicité mensongère contre la marque de crème solaire Coppertone aux Etats-Unis, accusée de faire croire à leurs utilisateurs qu'ils sont protégés contre les maladies de peau. Son étiquette est "clairement trompeuses" dans la mesure où elle fait croire que "la crème fait écran contre tous les méfaits des rayons solaires", alors qu'elle ne protège que contre les coups de soleil, a déclaré l'un des avocats. Les auteurs de la plainte demandent que des termes comme "écran total", "waterproof" ou toute autre déclaration prêtant à confusion disparaissent des étiquettes. Ils réclament aussi que le fabricant soit contraint de "restituer l'argent frauduleusement obtenu" en finançant une fondation pour la recherche sur les cancers de la peau.: | AFP |
| 2002 | Disinformation: PR campaign with Précision PR: public relations: P | CB-News |
| 2001 | ad budget: 236 million US$; | Advertising Age |
| 2000 | ad budget: 263 million US$; | Advertising Age |
|
|
|
&sa=OK&client=pub-2642534665785160&forid=1&channel=6290198667&ie=ISO-8859-1&oe=ISO-8859-1&flav=0002&sig=NuXwWEvBGZspbgPc&cof=GALT%3A%23CEA7FF%3BGL%3A1%3BDIV%3A%234A4A4A%3BVLC%3AFF6600%3BAH%3Acenter%3BBGC%3A4A4A4A%3BLBGC%3A4A4A4A%3BALC%3AFFB42D%3BLC%3AFFB42D%3BT%3AFFFFFF%3BGFNT%3AE8DBEF%3BGIMP%3ACEA7FF%3BLH%3A26%3BLW%3A304%3BL%3Ahttp%3A%2F%2Fwww.transnationale.org%2Fimages%2Ftrans2.gif%3BS%3Ahttp%3A%2F%2Fwww.transnationale.org%3BFORID%3A11&hl=en){kind=link}
&sa=OK&client=pub-2642534665785160&forid=1&channel=6290198667&ie=ISO-8859-1&oe=ISO-8859-1&flav=0002&sig=NuXwWEvBGZspbgPc&cof=GALT%3A%23CEA7FF%3BGL%3A1%3BDIV%3A%234A4A4A%3BVLC%3AFF6600%3BAH%3Acenter%3BBGC%3A4A4A4A%3BLBGC%3A4A4A4A%3BALC%3AFFB42D%3BLC%3AFFB42D%3BT%3AFFFFFF%3BGFNT%3AE8DBEF%3BGIMP%3ACEA7FF%3BLH%3A26%3BLW%3A304%3BL%3Ahttp%3A%2F%2Fwww.transnationale.org%2Fimages%2Ftrans2.gif%3BS%3Ahttp%3A%2F%2Fwww.transnationale.org%3BFORID%3A11&hl=en){kind=link}
